Cargando…

Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS

BACKGROUND: UK-5099 is a potent mitochondrial acetone carrier inhibitor, that exhibits anticancer activity. Recently, the anti-Toxoplasma gondii activity of UK-5099 was proposed, and in vivo studies of its pharmacokinetics in BALB/c mice are necessary to further evaluate the clinical effect of UK-50...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qingyuan, Si, Hongfei, Lv, Kun, Mo, Jiao, Wang, Xinnian, Yan, Biqing, Zhang, Jili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020015/
https://www.ncbi.nlm.nih.gov/pubmed/35443692
http://dx.doi.org/10.1186/s12917-022-03245-0
_version_ 1784689433833897984
author Zeng, Qingyuan
Si, Hongfei
Lv, Kun
Mo, Jiao
Wang, Xinnian
Yan, Biqing
Zhang, Jili
author_facet Zeng, Qingyuan
Si, Hongfei
Lv, Kun
Mo, Jiao
Wang, Xinnian
Yan, Biqing
Zhang, Jili
author_sort Zeng, Qingyuan
collection PubMed
description BACKGROUND: UK-5099 is a potent mitochondrial acetone carrier inhibitor, that exhibits anticancer activity. Recently, the anti-Toxoplasma gondii activity of UK-5099 was proposed, and in vivo studies of its pharmacokinetics in BALB/c mice are necessary to further evaluate the clinical effect of UK-5099. METHODS AND RESULTS: A simple and fast high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS) analysis method was established and verified in terms of its linearity, matrix effect, accuracy, precision, recovery and stability. The analytes were separated by an Agilent ZORBAX XDB-C18 column (2.1 × 50 mm, 3.5 μm) at 30 °C. A gradient mobile phase consisting of water with 0.1% formic acid (FA) (phase A) and acetonitrile (ACN) (phase B) was delivered at a flow rate of 0.40 mL·min(−1) with an injection volume of 5 μL. A good linear response was obtained in a concentration range of 5–5000 ng·mL(−1) (r(2) = 0.9947). The lower limit of quantification (LLOQ) was 5 ng·mL(−1). The extraction recovery of UK-5099 was greater than 95%. The inter- and intra-day accuracy and precision of the method showed relative standard deviations (RSDs) of less than 15%. This method has been successfully applied to the pharmacokinetic evaluation of UK-5099 in mouse plasma. In health mice, the main pharmacokinetic parameters of UK-5099 after intraperitoneal administration were measured using a noncompartmental model, in which the AUC(0-t) was 42,103 ± 12,072 ng·h·mL(−1) and the MRT(0-t) was 0.857 ± 0.143 h. The peak concentration (C(max)) was 82,500 ± 20,745 ng·h·mL(−1), which occurred at a peak time (T(max)) = 0.250 ± 0.000 h. CONCLUSIONS: A fast and sensitive HPLC–MS/MS method was developed, validated and successfully used for the determination of UK-5099 levels in mice after intraperitoneal administration. This study was the first report of the pharmacokinetic parameters of UK-5099 in mice, which will help to further study the administration of UK-5099 in animals and humans.
format Online
Article
Text
id pubmed-9020015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90200152022-04-21 Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS Zeng, Qingyuan Si, Hongfei Lv, Kun Mo, Jiao Wang, Xinnian Yan, Biqing Zhang, Jili BMC Vet Res Research BACKGROUND: UK-5099 is a potent mitochondrial acetone carrier inhibitor, that exhibits anticancer activity. Recently, the anti-Toxoplasma gondii activity of UK-5099 was proposed, and in vivo studies of its pharmacokinetics in BALB/c mice are necessary to further evaluate the clinical effect of UK-5099. METHODS AND RESULTS: A simple and fast high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS) analysis method was established and verified in terms of its linearity, matrix effect, accuracy, precision, recovery and stability. The analytes were separated by an Agilent ZORBAX XDB-C18 column (2.1 × 50 mm, 3.5 μm) at 30 °C. A gradient mobile phase consisting of water with 0.1% formic acid (FA) (phase A) and acetonitrile (ACN) (phase B) was delivered at a flow rate of 0.40 mL·min(−1) with an injection volume of 5 μL. A good linear response was obtained in a concentration range of 5–5000 ng·mL(−1) (r(2) = 0.9947). The lower limit of quantification (LLOQ) was 5 ng·mL(−1). The extraction recovery of UK-5099 was greater than 95%. The inter- and intra-day accuracy and precision of the method showed relative standard deviations (RSDs) of less than 15%. This method has been successfully applied to the pharmacokinetic evaluation of UK-5099 in mouse plasma. In health mice, the main pharmacokinetic parameters of UK-5099 after intraperitoneal administration were measured using a noncompartmental model, in which the AUC(0-t) was 42,103 ± 12,072 ng·h·mL(−1) and the MRT(0-t) was 0.857 ± 0.143 h. The peak concentration (C(max)) was 82,500 ± 20,745 ng·h·mL(−1), which occurred at a peak time (T(max)) = 0.250 ± 0.000 h. CONCLUSIONS: A fast and sensitive HPLC–MS/MS method was developed, validated and successfully used for the determination of UK-5099 levels in mice after intraperitoneal administration. This study was the first report of the pharmacokinetic parameters of UK-5099 in mice, which will help to further study the administration of UK-5099 in animals and humans. BioMed Central 2022-04-20 /pmc/articles/PMC9020015/ /pubmed/35443692 http://dx.doi.org/10.1186/s12917-022-03245-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zeng, Qingyuan
Si, Hongfei
Lv, Kun
Mo, Jiao
Wang, Xinnian
Yan, Biqing
Zhang, Jili
Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title_full Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title_fullStr Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title_full_unstemmed Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title_short Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC–MS/MS
title_sort determination and pharmacokinetics study of uk-5099 in mouse plasma by lc–ms/ms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020015/
https://www.ncbi.nlm.nih.gov/pubmed/35443692
http://dx.doi.org/10.1186/s12917-022-03245-0
work_keys_str_mv AT zengqingyuan determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT sihongfei determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT lvkun determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT mojiao determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT wangxinnian determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT yanbiqing determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms
AT zhangjili determinationandpharmacokineticsstudyofuk5099inmouseplasmabylcmsms